An Introduction to Systemic Sclerosis
Systemic sclerosis (SSc) is a rare, life-threatening, rheumatologic autoimmune disease characterised by fibrosis of the skin and multiple organ targets. Treatment strategies involve immunosuppressive and antifibrotic drugs but their efficacy is modest. Haematopoietic stem-cell transplantation reduces long-term mortality, but confers the risk of treatment-related mortality. Nintedanib has been approved to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with SSc, but does not affect skin fibrosis. Many novel therapeutic targets are emerging, including interleukin (IL) -6 (tocilizumab), IL-4 and IL-13, B cell pathology, and the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway. However, there remains no approved targeted therapies.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Systemic Sclerosis Content
Advances in the Treatment of Systemic Sclerosis
touchREVIEWS in RMD. 2022;2(1):61–9 DOI: https://doi.org/10.17925/RMD.2022.1.2.61
Advances continue to be made in the treatment of systemic sclerosis (SSc, also termed ‘scleroderma’); however, it remains a challenging disease for both patients and for the clinicians caring for them. The purpose of this review is to highlight these advances, as opposed to going into detail of the many different aspects of treatment of […]
Janet Pope, ACR 2022: Nintedanib for systemic sclerosis-associated interstitial lung disease – analysis of the SENSCIS Trial
The SENSCIS Trial (NCT02597933) was a phase 3 randomised, double-blind, placebo controlled study, which investigated the efficacy and safety of nintedanib in the treatment of patients with systemic sclerosis associated interstitial lung disease. In this touchIMMUNOLOGY interview, it was a pleasure to talk with Dr. Janet Pope (University of Western Ontario, London, ON, Canada) to discuss […]
Kathryn Torok, ACR 2021: Preliminary Data from Autologous Stem Cell Transplant in Juvenile-Onset Systemic Sclerosis
It was an absolute pleasure to speak with Professor Kathryn Torok (UPMC & University of Pittsburgh Scleroderma Center, University of Pittsburgh, Pittsburgh, PA, USA) around the initial safety and clinical responses of patients with juvenile-onset systemic sclerosis treated with CD34-selected peripheral blood ASCT (NCT03630211). This information is brought to you by Touch Medical Media and […]
Kathryn Torok, ACR 2021: Autologous Stem Cell Transplant in Treatment-Resistant Juvenile-onset Systemic Sclerosis
In this interview, we talk with Professor Kathryn Torok (UPMC & University of Pittsburgh Scleroderma Center, University of Pittsburgh, Pittsburgh, PA, USA) around CD34-selected peripheral blood ASCT in patients with juvenile-onset systemic sclerosis (NCT03630211). This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American […]
Dinesh Khanna, ACR 2020: Ziritaxestat in Cutaneous Systemic Sclerosis
touchIMMUNOLOGY caught up with Dinesh Khanna (University of Michigan, Ann Arbor, MI, USA) to discuss the results of the NOVESA Phase 2a study of ziritaxestat in cutaneous systemic sclerosis (NCT03798366). His abstract entitled ‘A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)’ was presented at the virtual ACR […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!